uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The implications of model-informed drug discovery and development for tuberculosis
UCL, Sch Life & Med Sci, London, England..
Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool, Merseyside, England..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.
Univ St Andrews, Sch Med, St Andrews, Fife, Scotland..
Show others and affiliations
2017 (English)In: Drug Discovery Today, ISSN 1359-6446, E-ISSN 1878-5832, Vol. 22, no 3, 481-486 p.Article, review/survey (Refereed) Published
Abstract [en]

Despite promising advances in the field and highly efficacious first-line treatment, an estimated 9.6 million people are still infected with tuberculosis (TB). Innovative methods are required to effectively transition the growing number of compounds into novel combination regimens. However, progression of compounds into patients occurs despite the lack of clear understanding of the pharmacokineticpharmacodynamic (PKPD) relationships. The PreDiCT-TB consortium was established in response to the existing gaps in TB drug development. The aim of the consortium is to develop new preclinical tools in concert with an in silico model-based approach, grounded in PKPD principles. Here, we highlight the potential impact of such an integrated framework on the various stages of TB drug development and on the dose rationale for drug combinations.

Place, publisher, year, edition, pages
ELSEVIER SCI LTD , 2017. Vol. 22, no 3, 481-486 p.
National Category
Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:uu:diva-321061DOI: 10.1016/j.drudis.2016.09.004ISI: 000398139200003PubMedID: 27693714OAI: oai:DiVA.org:uu-321061DiVA: diva2:1092941
Funder
EU, FP7, Seventh Framework Programme
Available from: 2017-05-04 Created: 2017-05-04 Last updated: 2017-05-04Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Simonsson, Ulrika S.H.
By organisation
Department of Pharmaceutical Biosciences
In the same journal
Drug Discovery Today
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 147 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf